Pharmaceutical Analytical Testing Market, By Service Type (Bioanalytical Testing, Method Development and Validation, Stability Testing, Drug Substances Testing, and Others), By End User (Biopharmaceutical Companies, Contract Research Organizations, Medical Device Companies, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jun 2024

Code : CMI5383

Pages :173

Formats :

Excel and PDF

Industry : Medical Devices

Key Developments

On March 13, 2024, LGM Pharma, a leading contract development and manufacturing organization (CDMO), revealed a significant investment exceeding $2 million in its analytical testing services. This investment accompanies a 50% expansion in offerings. Additionally, the company will introduce suppository manufacturing capabilities and extend its facility in Rosenburg, Texas. These advancements aim to provide customers with more efficient and comprehensive manufacturing solutions.
On 4 March 2024, SCHOTT Pharma’s PartnerLab, a shop for drug developers, offers a comprehensive suite of analytical tests crucial for drug submission, aiding pharmaceutical companies in navigating complexity, ensuring product quality, and accelerating market entry. Registered with the FDA as an independent lab, SCHOTT Pharma streamlines drug submission processes for its partners.
In July 2023, Recipharm, a global contract development and manufacturing organization (CDMO), has inaugurated a new analytical laboratory in Bengaluru, India. This investment addresses the growing demand for reliable testing services, filling a crucial market need and prioritizing product safety, regulatory compliance, consumer protection, and patient well-being.
In March 2022, American Association for Cancer Research (AACR) annual meeting, Transgene, a French biotech company, is set to present a poster featuring promising preliminary Phase 1 data on TG4050, its individual Neoantigen cancer vaccine.
In March 2021, Teracero Pharma Inc., a pharmaceutical company in collaboration with its German partner nal von Minden GmbH, specialist for in-vitro diagnostics disclosed that Health Canada granted authorization for the importation and commercialization of nal von Minden’s NADAL COVID-19 IgG/IgM Test.